| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S0140-6736(94)90755-2 |
| P698 | PubMed publication ID | 7967990 |
| P50 | author | Ann-Mari Svennerholm | Q4981458 |
| César Cabezas | Q64868891 | ||
| P2093 | author name string | D M Watts | |
| B Vasquez | |||
| D N Taylor | |||
| J C Sadoff | |||
| R Meza | |||
| J L Sanchez | |||
| G Castellares | |||
| R E Begue | |||
| P2860 | cites work | Genetic susceptibility to cholera | Q41022523 |
| Safety and immunogenicity of an oral recombinant cholera B subunit-whole cell vaccine in Swedish volunteers | Q41899134 | ||
| ABO blood groups and cholera | Q44659524 | ||
| Field trial of oral cholera vaccines in Bangladesh | Q46726270 | ||
| New cholera vaccines | Q47584366 | ||
| B subunit-whole cell and whole cell-only oral vaccines against cholera: studies on reactogenicity and immunogenicity. | Q54768645 | ||
| Field Trial of Oral Cholera Vaccines in Bangladesh: Results of One Year of Follow-Up | Q57926677 | ||
| ABO blood groups and cholera: new observations on specificity of risk and modification of vaccine efficacy | Q57933076 | ||
| Cholera and blood-groups | Q66696048 | ||
| Safety and immunogenicity of the oral, whole cell/recombinant B subunit cholera vaccine in North American volunteers | Q70735658 | ||
| Cost-effectiveness and cost-benefit analyses of vaccines | Q71578652 | ||
| Evaluation of different immunization schedules for oral cholera B subunit-whole cell vaccine in Swedish volunteers | Q93875922 | ||
| P433 | issue | 8932 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | military | Q8473 |
| cholera | Q12090 | ||
| vaccine | Q134808 | ||
| P304 | page(s) | 1273-1276 | |
| P577 | publication date | 1994-11-01 | |
| P1433 | published in | The Lancet | Q939416 |
| P1476 | title | Protective efficacy of oral whole-cell/recombinant-B-subunit cholera vaccine in Peruvian military recruits | |
| P478 | volume | 344 |
| Q53311743 | 5 year efficacy of a bivalent killed whole-cell oral cholera vaccine in Kolkata, India: a cluster-randomised, double-blind, placebo-controlled trial. |
| Q84941568 | A case for control of cholera in Africa by vaccination |
| Q79815991 | A proteoliposome based formulation administered by the nasal route produces vibriocidal antibodies against El Tor Ogawa Vibrio cholerae O1 in BALB/c mice |
| Q41604561 | A review of the design of vaccine efficacy trials and a proposal for the design of the VA Cooperative Study of Active Immunotherapy of HIV Infection |
| Q36551627 | A single dose of live oral cholera vaccine CVD 103-HgR is safe and immunogenic in HIV-infected and HIV-noninfected adults in Mali |
| Q33975799 | Active immunization in the United States: developments over the past decade |
| Q36904890 | Acute infectious pediatric gastroenteritis: beyond oral rehydration therapy |
| Q46167369 | An affordable cholera vaccine: an important step forward |
| Q35066200 | Antigen-specific memory B-cell responses in Bangladeshi adults after one- or two-dose oral killed cholera vaccination and comparison with responses in patients with naturally acquired cholera |
| Q38680503 | Antimicrobial Resistance Risks of Cholera Prophylaxis for United Nations Peacekeepers |
| Q35802790 | Biosafety aspects of the recombinant live oral Vibrio cholerae vaccine strain CVD 103-HgR. |
| Q40560650 | British HIV Association Guidelines on the Use of Vaccines in HIV-Positive Adults 2015. |
| Q78754511 | Can needle-free administration of vaccines become the norm in global immunization? |
| Q36525462 | Characterization of Vibrio cgolerae non-O1 serogroups obtained from an outbreak of diarrhea in Lima, Peru. |
| Q55878773 | Cholera |
| Q55890255 | Cholera |
| Q73620155 | Cholera |
| Q36522758 | Cholera in Haiti: reproductive numbers and vaccination coverage estimates |
| Q36732913 | Cholera: assessing the risk to travellers and identifying methods of protection |
| Q39830017 | Comparison of alternative buffers for use with a new live oral cholera vaccine, Peru-15, in outpatient volunteers |
| Q40703640 | Cost of immunization with a locally produced, oral cholera vaccine in Viet Nam. |
| Q43369067 | Cost-benefit comparisons of investments in improved water supply and cholera vaccination programs |
| Q40145989 | Coverage and cost of a large oral cholera vaccination program in a high-risk cholera endemic urban population in Dhaka, Bangladesh |
| Q26823170 | Critical analysis of compositions and protective efficacies of oral killed cholera vaccines |
| Q101163385 | Development of Hillchol®, a low-cost inactivated single strain Hikojima oral cholera vaccine |
| Q44235991 | Efficacy and safety of a modified killed-whole-cell oral cholera vaccine in India: an interim analysis of a cluster-randomised, double-blind, placebo-controlled trial |
| Q36444089 | Enteric infections and the vaccines to counter them: future directions |
| Q37062508 | Epidemic cholera in the new world: translating field epidemiology into new prevention strategies |
| Q33767334 | Escherichia coli. EAEC, EHEC, EIEC, ETEC. |
| Q38979270 | Evidence for CVD 103-HgR as an effective single-dose oral cholera vaccine |
| Q33760095 | Immune responses in ileostomy fluid and serum after oral cholera vaccination of patients colectomized because of ulcerative colitis. |
| Q35440298 | Immunogenicity and protective efficacy of a prototype Campylobacter killed whole-cell vaccine in mice |
| Q34003291 | Immunogenicity of the B monomer of Escherichia coli heat-labile toxin expressed on the surface of Streptococcus gordonii. |
| Q30151668 | Improving immunization approaches to cholera |
| Q45958574 | Intranasal administration of proteoliposome-derived cochleates from Vibrio cholerae O1 induce mucosal and systemic immune responses in mice. |
| Q34087755 | Killed oral cholera vaccines: history, development and implementation challenges |
| Q33992027 | Kinetics of local and systemic immune responses to an oral cholera vaccine given alone or together with acetylcysteine |
| Q59354719 | Measurement of Vaccine Direct Effects under the Test-Negative Design |
| Q33927450 | Meeting cholera's challenge to Haiti and the world: a joint statement on cholera prevention and care |
| Q35091566 | Methods to assess the impact of mass oral cholera vaccination campaigns under real field conditions |
| Q36575296 | Molecular evolution of Vibrio cholerae O1 strains isolated in Lima, Peru, from 1991 to 1995. |
| Q37953796 | New-generation vaccines against cholera |
| Q33427647 | Oral cholera vaccine use in Zanzibar: socioeconomic and behavioural features affecting demand and acceptance |
| Q36489754 | Oral cholera vaccines: use in clinical practice |
| Q30401927 | Oral vaccines against cholera |
| Q24235775 | Oral vaccines for preventing cholera |
| Q33213069 | Policymakers' views regarding the introduction of new-generation vaccines against typhoid fever, shigellosis and cholera in Asia |
| Q34456242 | Post-licensure deployment of oral cholera vaccines: a systematic review |
| Q36690265 | Present and future cholera vaccines |
| Q46974317 | Private demand for cholera vaccines in Beira, Mozambique |
| Q39448785 | Protection against cholera from killed whole-cell oral cholera vaccines: a systematic review and meta-analysis |
| Q47987537 | Reduction of travellers' diarrhoea by WC/rBS oral cholera vaccine in young, high-risk travellers |
| Q35513729 | Relative significance of mannose-sensitive hemagglutinin and toxin-coregulated pili in colonization of infant mice by Vibrio cholerae El Tor. |
| Q40501431 | Safety and immunogenicity of an oral, inactivated, whole-cell vaccine for Shigella sonnei: preclinical studies and a Phase I trial |
| Q36631261 | Social and cultural determinants of oral cholera vaccine uptake in Zanzibar |
| Q28552894 | Strategies to Prevent Cholera Introduction during International Personnel Deployments: A Computational Modeling Analysis Based on the 2010 Haiti Outbreak |
| Q38959870 | Surface display on lactic acid bacteria without genetic modification: strategies and applications |
| Q57481187 | The Euvichol story - Development and licensure of a safe, effective and affordable oral cholera vaccine through global public private partnerships |
| Q35754539 | The Impact of a One-Dose versus Two-Dose Oral Cholera Vaccine Regimen in Outbreak Settings: A Modeling Study |
| Q74766273 | The pregnant traveler |
| Q36856016 | The true burden and risk of cholera: implications for prevention and control |
| Q37633392 | Travellers' diarrhoea - pros and cons of different prophylactic measures |
| Q34474623 | Urban cholera transmission hotspots and their implications for reactive vaccination: evidence from Bissau city, Guinea bissau |
| Q39235173 | Vaccination in emergencies |
| Q34787413 | Vaccination with Dukoral against travelers' diarrhea (ETEC) and cholera |
| Q53581992 | Vaccine potential for inactivated shigellae. |
| Q39217803 | Vaccines against cholera, typhoid fever and shigellosis for developing countries |
| Q33908873 | Vaccines for preventing cholera |
Search more.